observational
1993
Nicotinamide adenine dinucleotide (NADH)--a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application
Birkmayer JGD, Vrecko C, Volc D, Birkmayer W
Published in Acta Neurologica Scandinavica Supplementum, Vol. 146, pp. 32-5
Key Findings
About half of treated Parkinson's patients showed some improvement in disability scores after NADH, with the parenteral route appearing more effective.
Conclusions
Historical uncontrolled data that has never been replicated in a blinded trial.
Limitations
Open label, no control group.
Supplements Studied
NADH
Compound
About half of treated Parkinson's patients improved in an uncontrolled open-label NADH evaluation.
Related Health Concerns
Study Details
Year:1993
Sample Size:885
Quality Score:2/10
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.